Healthcare / Drug Manufacturers - Specialty & GenericThailand
$0.39
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-17.4M · quality 61.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.2B
P/E
N/A
•EV/EBITDA
15.0x
↑ROE
-2.9%
↓Gross Margin
87.4%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+161.3%
FCF CAGR
—
FCF margin
-4.8%
FCF / Net income
0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $234.5M · net income $-13.3M · FCF $-11.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $234.5M | $234.5M | $549032.00 | $5.1M | $13.1M |
| Net Income | $-13.3M | $-13.3M | $-48.5M | $-1.38B | $-73.5M |
| EBITDA | $79.8M | $79.8M | $-36.5M | $-1.38B | $-67.6M |
| EPS | -0.00 | -0.00 | -0.02 | -0.50 | -0.03 |
| Gross Margin | 87.4% | 87.4% | -1953.6% | -422.2% | -31.5% |
| Operating Margin | 25.0% | 25.0% | -7685.9% | -24661.7% | -472.4% |
| Net Margin | -5.7% | -5.7% | -8826.3% | -27015.0% | -559.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.06 | 0.03 | 0.00 |
| Current Ratio | 1.93 | 1.93 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-11.2M | $-11.2M | $-17.4M | $-72.8M | $-192.8M |
| Returns | |||||
| ROE | -2.9% | -2.9% | -23.7% | -547.8% | -4.5% |
| Valuation | |||||
| EV/EBITDA | 14.97 | 14.97 | — | — | — |
| P/B | 3.12 | 3.12 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 42604.4% | 42604.4% | -89.3% | -61.0% | — |
| EPS Growth | 79.3% | 79.3% | 96.5% | -1672.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → -0.00
Residual
+0.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.